Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | IDE | P14735 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28247431 | 0.83 | CYP3A4 (0.50) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL15260220 | 0.81 | MAPT (0.43) | OPRM1BRD4OPRD1OPRK1SLC22A1 | |
| SCHEMBL15260026 | 0.81 | TRPV1 (0.44) | OPRM1OPRD1KCNH2 | |
| SCHEMBL15260216 | 0.77 | RAB9A (0.47) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL1282238 | 0.75 | OPRM1 (0.39) | PANK3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL15260099 | 0.75 | PIK3CA (0.40) | OPRM1BRD4OPRD1OPRK1SLC22A1 | |
| SCHEMBL3315322 | 0.75 | CYP2C9 (0.51) | KDM4E | |
| SCHEMBL7386664 | 0.74 | PANK3 (0.48) | PANK3PTPN11KDM4E | |
| SCHEMBL10235764 | 0.74 | PIK3CA (0.50) | OPRM1BRD4OPRD1OPRK1SLC22A1 | |
| SCHEMBL1283047 | 0.74 | PIK3CA (0.47) | OPRM1BRD4OPRD1OPRK1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | disclosed |
| EP-2828257-B1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2017-07-26 | — | — | EP | disclosed |
| EP-2828257-B1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2017-07-26 | — | — | EP | disclosed |
| US-9604976-B2 | Antibacterial compounds | SPERO GYRASE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604976-B2 | Antibacterial compounds | SPERO GYRASE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604976-B2 | Antibacterial compounds | SPERO GYRASE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | SPERO GYRASE, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | SPERO GYRASE, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | SPERO GYRASE, INC. | 2015-11-19 | — | — | US | disclosed |
| US-8906902-B2 | Antibacterial compounds | BIOTA EUROPE LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8906902-B2 | Antibacterial compounds | BIOTA EUROPE LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8906902-B2 | Antibacterial compounds | BIOTA EUROPE LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20130252938-A1 | Antibacterial Compounds | BIOTA EUROPE LTD. (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252938-A1 | Antibacterial Compounds | BIOTA EUROPE LTD. (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252938-A1 | Antibacterial Compounds | BIOTA EUROPE LTD. (GB) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | STS, PGLS, PEPD | PANK3 1810/4885OPRM1 995/4885BRD4 3549/4885 |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | STS, PEPD, PGLS | PANK3 1010/4885OPRM1 1226/4885BRD4 3804/4885 |
| US-20130252938-A1 | Antibacterial Compounds | STS, PGLS, PEPD | PANK3 1810/4885OPRM1 995/4885BRD4 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.